Novartis signs $3.2bn drug delivery deal with Alteogen
Pharmaceutical Technology
Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of subcutaneous drug formulations using Alteogen's ALT-B4 technology.
pharminent
September 3, 2026 (Last updated: September 3, 2026)
Pharmaceutical Technology
Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of subcutaneous drug formulations using Alteogen’s ALT-B4 technology.